You are here


Biolidics shares sink 22% after calling off US sales of Covid-19 test kits


BIOLIDICS shares sank 22 per cent on Monday after the Catalist-listed firm announced on Sunday that it had mutually agreed with Aytu BioScience to terminate a distribution agreement for its Covid-19 antibody test kits in the US, amid increased competition for such kits.


BT is now on Telegram!

For daily updates on weekdays and specially selected content for the weekend. Subscribe to